pancreatic neuroendocrine tumor G1

Summary

pancreatic neuroendocrine tumor G1 (MONDO:0021535) is a cancer and 3 clinical trials. Top therapeutic interventions include bevacizumab, lutetium oxodotreotide lu-177, and octreotide acetate. A subtype of carcinoid tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic neuroendocrine tumor G1
Mondo ID	MONDO:0021535
NCIT	C95584
SNOMED CT	254613007
UMLS	C2987241
MedGen	459467
GARD	0025333
Anatomy (UBERON)	UBERON:0001264
Is cancer (heuristic)	yes

Also known as: grade 1 neuroendocrine neoplasm of pancreas · pancreas carcinoid tumor · pancreas carcinoid tumour · pancreas NET G1 · pancreas neuroendocrine neoplasm G1 · pancreas neuroendocrine tumor, well differentiated, low grade · pancreatic NET G1 · pancreatic neuroendocrine tumor G1

Disease family

This is a subtype of carcinoid tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › neuroendocrine neoplasm › carcinoid tumor › pancreatic neuroendocrine tumor G1

Related subtypes (6): lung carcinoid tumor, atypical carcinoid tumor, gastric neuroendocrine tumor G1, somatostatinoma, intestinal neuroendocrine tumor G1, childhood carcinoid tumor

Subtypes (1): enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06016855	PHASE4	RECRUITING	Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
NCT01229943	PHASE2	COMPLETED	Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
NCT02893930	PHASE2	COMPLETED	Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
LUTETIUM OXODOTREOTIDE LU-177	4	1
OCTREOTIDE ACETATE	4	1
SAPANISERTIB	2	1
CHEMBL3962632	0	1
CHEMBL3991933	0	1